NCT03813719 is a clinical trial in Endometrial Cancer, sponsored by Imperial College London.

Who is sponsoring NCT03813719?

NCT03813719 is sponsored by Imperial College London.

What condition does NCT03813719 study?

NCT03813719 studies Endometrial Cancer, Cancer, Uterine Cancer, Anxiety, Stress, Psychological.

Is NCT03813719 still recruiting?

NCT03813719 is currently completed. Last updated 14 July 2020.

Are results published for NCT03813719?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-07-14 · How we verify

NCT03813719

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anxiety and Distress Levels in Women With Suspected Endometrial Cancer

Completed Results posted Last updated 14 July 2020

What this trial tests

trial in Endometrial Cancer in 250 participants. Completed in 1 August 2019.

Timeline

1 July 2018

Primary endpoint
1 July 2019

1 August 2019

Quick facts

Lead sponsor	Imperial College London
Status	Completed
Study type	OBSERVATIONAL
Enrollment	250
Start date	1 July 2018
Primary completion	1 July 2019
Estimated completion	1 August 2019
Sites	1 location across United Kingdom

Conditions studied

Endometrial Cancer — all drugs for Endometrial Cancer →
Cancer — all drugs for Cancer →
Uterine Cancer — all drugs for Uterine Cancer →
Anxiety — all drugs for Anxiety →

Sponsor

Imperial College London

Who can join

18 and older, female only, with Endometrial Cancer or Cancer. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Anxiety Score for Patients Attending Clinic Primary · Immediately before clinic (waiting room)

GAD 7 score - (Generalised Anxiety Disorder assessment 7 score). 7 items each measured and score summated. Scale 0-21.Cut offs 0-5, 6-10, 11-15, 16+ correlate with anxiety score. Higher levels = worse anxiety

Group	Value	95% CI
All Patients Attending Rapid Access Gynaecology Clinic	6	3 – 12

Pain Score if Needing a Tissue Biopsy Secondary · Immediately after tissue sample taken.

Patients asked to rank Pain score (using visual analogue score standardised tool), 0 to 10 score, where 0 is no pain and 10 is the worst pain in their life.

Group	Value	95% CI
All Patients Attending Rapid Access Gynaecology Clinic	5.5	3 – 8

Time Taken for Tissue Sample to be Performed Secondary · During tissue biopsy time

Measure time taken to perform tissue sample (in minutes) from insertion to removal of speculum.

Group	Value	95% CI
All Patients Attending Rapid Access Gynaecology Clinic	5.5	3 – 8

Sponsor's own description

Patients attending the rapid access gynaecology clinic with a suspicion of endometrial cancer are understandably nervous. Few studies have quantified anxiety and distress of patients in this group. This study surveys anxiety and stress levels of women attending clinic (by filling in an anonymous questionnaire). Additionally, in women who need a tissue biopsy, women are asked to rate their pain scores.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Endometrial Cancer

Currently open trials in the same condition.

NCT07419841 — A Phase 1 Study of the Safety and Tolerability of CTX-10726 · Phase 1 · recruiting
NCT07382583 — Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the P · recruiting
NCT07377734 — Intrauterine Injection of Type III Collage in FST of EC/AEH · Phase 2 · recruiting
NCT07319429 — Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification · Phase 2, PHASE3 · recruiting
NCT07397624 — Endoscopic Suture Gastroplasty (ESG) for Treatment of Obese Patients With Endometrial Cancer · recruiting

Other Imperial College London trials

Trials by the same sponsor.

NCT06035861 — Endothelial Cell Activation and Total Pulmonary Resistance in PAH · NA · not yet recruiting
NCT07397455 — Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants · Phase 1 · not yet recruiting
NCT07422532 — A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing · NA · not yet recruiting
NCT07389031 — Maralixibat for Intrahepatic Cholestasis of Pregnancy · Phase 2 · not yet recruiting
NCT07358897 — Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03813719 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Imperial College London
Last refreshed: 14 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03813719.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing